These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

176 related items for PubMed ID: 8986917

  • 1. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril.
    Holwerda NJ, Fogari R, Angeli P, Porcellati C, Hereng C, Oddou-Stock P, Heath R, Bodin F.
    J Hypertens; 1996 Sep; 14(9):1147-51. PubMed ID: 8986917
    [Abstract] [Full Text] [Related]

  • 2. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin-converting enzyme inhibitor, lisinopril.
    Black HR, Graff A, Shute D, Stoltz R, Ruff D, Levine J, Shi Y, Mallows S.
    J Hum Hypertens; 1997 Aug; 11(8):483-9. PubMed ID: 9322828
    [Abstract] [Full Text] [Related]

  • 3. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared to hydrochlorothiazide.
    Hegner G, Faust G, Freytag F, Meilenbrock S, Sullivan J, Bodin F.
    Eur J Clin Pharmacol; 1997 Aug; 52(3):173-7. PubMed ID: 9218922
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of valsartan compared with enalapril at different altitudes.
    Botero R, Matiz H, María E, Orejarena H, Blanco M, Velez JR, Del Portillo H.
    Int J Cardiol; 2000 Feb 15; 72(3):247-54. PubMed ID: 10716135
    [Abstract] [Full Text] [Related]

  • 5. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.
    Corea L, Cardoni O, Fogari R, Innocenti P, Porcellati C, Provvidenza M, Meilenbrock S, Sullivan J, Bodin F.
    Clin Pharmacol Ther; 1996 Sep 15; 60(3):341-6. PubMed ID: 8841157
    [Abstract] [Full Text] [Related]

  • 6. Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension.
    Tikkanen I, Omvik P, Jensen HA.
    J Hypertens; 1995 Nov 15; 13(11):1343-51. PubMed ID: 8984133
    [Abstract] [Full Text] [Related]

  • 7. Valsartan and hydrochlorothiazide in patients with essential hypertension. A multiple dose, double-blind, placebo controlled trial comparing combination therapy with monotherapy.
    Benz JR, Black HR, Graff A, Reed A, Fitzsimmons S, Shi Y.
    J Hum Hypertens; 1998 Dec 15; 12(12):861-6. PubMed ID: 9883710
    [Abstract] [Full Text] [Related]

  • 8. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension.
    Philipp T, Smith TR, Glazer R, Wernsing M, Yen J, Jin J, Schneider H, Pospiech R.
    Clin Ther; 2007 Apr 15; 29(4):563-80. PubMed ID: 17617280
    [Abstract] [Full Text] [Related]

  • 9. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension.
    Oparil S, Dyke S, Harris F, Kief J, James D, Hester A, Fitzsimmons S.
    Clin Ther; 1996 Apr 15; 18(5):797-810. PubMed ID: 8930424
    [Abstract] [Full Text] [Related]

  • 10. Valsartan, a new angiotensin II antagonist; blood pressure reduction in essential hypertension compared with an angiotensin converting enzyme inhibitor, enalapril.
    Mallion JM, Boutelant S, Chabaux P, Baguet JP, Muller M, Meilenbrock S, Heath R, Bodin F.
    Blood Press Monit; 1997 Aug 15; 2(4):179-184. PubMed ID: 10234113
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM, Malacco E, Khder Y, Kandra A, Bönner G, Heintz D.
    Clin Ther; 2005 May 15; 27(5):578-87. PubMed ID: 15978306
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Dose-response efficacy of valsartan, a new angiotensin II receptor blocker.
    Pool JL, Glazer R, Chiang YT, Gatlin M.
    J Hum Hypertens; 1999 Apr 15; 13(4):275-81. PubMed ID: 10333347
    [Abstract] [Full Text] [Related]

  • 16. A comparison of the angiotensin II antagonists valsartan and losartan in the treatment of essential hypertension.
    Hedner T, Oparil S, Rasmussen K, Rapelli A, Gatlin M, Kobi P, Sullivan J, Oddou-Stock P.
    Am J Hypertens; 1999 Apr 15; 12(4 Pt 1):414-7. PubMed ID: 10232502
    [Abstract] [Full Text] [Related]

  • 17. Comparison of valsartan 160 mg with lisinopril 20 mg, given as monotherapy or in combination with a diuretic, for the treatment of hypertension: the Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril (PREVAIL) study.
    Malacco E, Santonastaso M, Varì NA, Gargiulo A, Spagnuolo V, Bertocchi F, Palatini P, Blood Pressure Reduction and Tolerability of Valsartan in Comparison with Lisinopril Study.
    Clin Ther; 2004 Jun 15; 26(6):855-65. PubMed ID: 15262456
    [Abstract] [Full Text] [Related]

  • 18. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
    Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF.
    J Hypertens; 2000 Jan 15; 18(1):89-95. PubMed ID: 10678548
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study.
    Giles TD, Weber MA, Basile J, Gradman AH, Bharucha DB, Chen W, Pattathil M, NAC-MD-01 Study Investigators.
    Lancet; 2014 May 31; 383(9932):1889-98. PubMed ID: 24881993
    [Abstract] [Full Text] [Related]

  • 20. Losartan versus valsartan in the treatment of patients with mild to moderate essential hypertension: data from a multicenter, randomized, double-blind, 12-week trial.
    Elliott WJ, Calhoun DA, DeLucca PT, Gazdick LP, Kerns DE, Zeldin RK.
    Clin Ther; 2001 Aug 31; 23(8):1166-79. PubMed ID: 11558856
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.